Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
WV

NASDAQ · WVE

Wave Life Sciences Ltd.

Healthcare · Biotechnology

$5.41

Up+$0.21 (+4.04%)

Updated Aug 15, 2026, 7:36 PM

SID Score

3.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.75B
P/E ratio
-23.03
Dividend yield
0.00%
52-week range
$5.01 – $14.32
Volume
2.88M
Avg. volume
5.46M

Price performance

WVE price history

1M range · 21 trading sessions · Daily adjusted prices

WVE closed at $5.41 after 21 trading sessions, down 7.04% for the selected period.

Last close
$5.41
Period change
-7.04%
Period low
$5.05
Period high
$6.10
Daily close
View OHLC price history
WVE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 14, 2026$5.16$5.42$5.14$5.412.88M
Aug 13, 2026$5.25$5.46$5.17$5.206.06M
Aug 12, 2026$5.30$5.43$5.09$5.245.21M
Aug 11, 2026$6.01$6.115$5.01$5.0456.92M
Aug 10, 2026$6.41$6.41$6.01$6.072.57M
Aug 7, 2026$6.15$6.157$5.92$6.104.56M
Aug 6, 2026$5.93$6.15$5.93$6.021.66M
Aug 5, 2026$6.04$6.05$5.845$5.931.84M
Aug 4, 2026$5.75$6.015$5.67$6.002.26M
Aug 3, 2026$5.55$5.77$5.36$5.743.42M
Jul 31, 2026$5.65$5.75$5.37$5.512.87M
Jul 30, 2026$5.62$5.77$5.47$5.763.04M
Jul 29, 2026$5.84$5.9326$5.66$5.812.3M
Jul 28, 2026$5.92$5.975$5.7814$5.892.81M
Jul 27, 2026$5.92$6.12$5.8828$5.921.93M
Jul 24, 2026$5.80$5.8924$5.74$5.812.07M
Jul 23, 2026$5.63$5.805$5.63$5.782.22M
Jul 22, 2026$5.79$5.84$5.669$5.742.13M
Jul 21, 2026$5.70$5.8599$5.70$5.791.45M
Jul 20, 2026$5.83$5.96$5.72$5.731.33M
Jul 17, 2026$5.57$5.85$5.51$5.822.12M

Latest WVE news

The latest Smart Investors Daily articles mentioning WVE.

Stock researchCompany · Overview

WVE research

Overview

Company profile and research snapshot.

Company profile

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.22
Implied upside
—
Analysts
—
WVE recent ratings
DateFirmRatingTarget
Aug 4, 2026MizuhoOutperform—
Jul 31, 2026B. Riley SecuritiesBuy—
Jul 31, 2026WedbushOutperform—
Jul 31, 2026CitigroupBuy—
May 20, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 7, 2026

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...

Yahoo · Aug 5, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approvals required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arran

Yahoo · Aug 4, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in August. BofA Securities 2026 SMID Cap Executive Insights EventDate: Tuesday, August 11, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By